Anti-Cancer Agent Tarceva, Obtained Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations in Japan
Please find attached a press release by Chugai
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Tarceva